• Explore /
  • Poster
  • / A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

National Cancer Center Hospital East, Chiba, Japan

Kohei Shitara , Yung-Jue Bang , Hyun Cheol Chung , Hiroshi Yabusaki , Satoru Iwasa , Daisuke Sakai , Kei Muro , Naotoshi Sugimoto , Hisateru Yasui , Makio Gamoh , Yasuko Murakawa , Yuji Negoro , Tomohiro Nishina , Hisashi Hosaka , Yasushi Omuro , Yoshinori Kawaguchi , Masahiro Sugihara , Kaku Saito , Rita Dalal , Kensei Yamaguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT03329690

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr TPS180)

DOI

10.1200/JCO.2019.37.4_suppl.TPS180

Abstract #

TPS180

Poster Bd #

N12

Abstract Disclosures

Similar Posters

First Author: Kensei Yamaguchi

First Author: Kensei Yamaguchi

First Author: Zhi Peng

First Author: Yelena Y. Janjigian